Search results
Showing 76 to 90 of 529 results for drug monitoring
This quality standard covers the prevention or delay of harmful use of drugs by children, young people and adults most likely to start using drugs, or already experimenting or using drugs occasionally. This includes illegal psychoactive substances, solvents, volatile substances, image- and performance-enhancing drugs, prescription-only medicines and over-the-counter medicines. It describes high-quality care in priority areas for improvement.
View quality statements for QS165Show all sections
Sections for QS165
- Quality statements
- Quality statement 1: Assessment of looked-after children and young people
- Quality statement 2: Assessment of care leavers
- Quality statement 3: Assessment of children and young people in contact with youth offending services
- Quality statement 4: Information and advice for adults
- Update information
- About this quality standard
Edoxaban for treating and for preventing deep vein thrombosis and pulmonary embolism (TA354)
Evidence-based recommendations on edoxaban (Lixiana) for treating deep vein thrombosis and pulmonary embolism in adults and preventing them happening again.
Evidence-based recommendations on galcanezumab (Emgality) for preventing migraine in adults.
Evidence-based recommendations on lenalidomide (Revlimid) for maintenance treatment after an autologous stem cell transplant for newly diagnosed multiple myeloma in adults.
This quality standard covers assessing, diagnosing and managing rheumatoid arthritis in over 16s. It describes high-quality care in priority areas for improvement.
This quality standard covers managing acute painful episodes of sickle cell disease in hospital. It includes pain relief and care for children, young people and adults, from presentation in hospital until discharge. It describes high-quality care in priority areas for improvement.
View quality statements for QS58Show all sections
Sections for QS58
- Quality statements
- Quality statement 1: Timely assessment and analgesia
- Quality statement 2: Regular assessment of pain relief
- Quality statement 3: Strong opioids and monitoring
- Quality statement 4: Acute complications
- Quality statement 5: Protocols and specialist support
- Quality statement 6: Discharge information
- Update information
This guideline covers diagnosing and managing cystic fibrosis. It specifies how to monitor the condition and manage the symptoms to improve quality of life. There are also detailed recommendations on treating the most common infections in people with cystic fibrosis.
This guideline covers safe and effective use of medicines in health and social care for people taking 1 or more medicines. It aims to ensure that medicines provide the greatest possible benefit to people by encouraging medicines reconciliation, medication review, and the use of patient decision aids.
Diabetes in pregnancy: management from preconception to the postnatal period (NG3)
This guideline covers managing diabetes and its complications in women who are planning pregnancy or are already pregnant. It aims to improve the diagnosis of gestational diabetes and help women with diabetes to self-manage their blood glucose levels before and during pregnancy.
Irritable bowel syndrome in adults: diagnosis and management (CG61)
This guideline covers diagnosing and managing irritable bowel syndrome (IBS) in people aged 18 and over. It details how to accurately diagnose IBS, and aims to improve the quality of life for adults with IBS by promoting effective management using dietary and lifestyle advice, pharmacological therapy and referral for psychological interventions.
Antimicrobial prescribing: oritavancin for acute bacterial skin and skin structure infections (ES39)
Summary of the evidence on oritavancin for acute bacterial skin and skin structure infections (ABSSSI) in adults
Specialist neonatal respiratory care for babies born preterm (NG124)
This guideline covers specific aspects of respiratory support (for example, oxygen supplementation, assisted ventilation, treatment of some respiratory disorders, and aspects of monitoring) for preterm babies in hospital.
Voclosporin with mycophenolate mofetil for treating lupus nephritis (TA882)
Evidence-based recommendations on voclosporin (Lupkynis) with mycophenolate mofetil for treating lupus nephritis in adults.
This quality standard covers diagnosing and managing attention deficit hyperactivity disorder (ADHD) in adults, young people and children (aged 3 and over). It describes high-quality care in priority areas for improvement.
View quality statements for QS39Show all sections
Sections for QS39
- Quality statements
- Quality statement 1: Confirmation of diagnosis
- Quality statement 2: Identification and referral in adults
- Quality statement 3: Continuity of child to adult services
- Quality statement 4: Parent training programmes
- Quality statement 5: Psychological treatments for children and young people
- Quality statement 6: Starting drug treatment
- Quality statement 7: Annual review of drug treatment
Evidence-based recommendations on mepolizumab (Nucala) for treating severe eosinophilic asthma in adults.